Ιρλανδία - Αγγλικά - HPRA (Health Products Regulatory Authority)

norgine b.v. - dantrolene sodium - capsule, hard - 25 milligram(s) - dantrolene and derivatives; dantrolene

Ιρλανδία - Αγγλικά - HPRA (Health Products Regulatory Authority)

norgine b.v. - dantrolene sodium - powder for solution for injection - 20 milligram(s) - dantrolene and derivatives; dantrolene

Ιρλανδία - Αγγλικά - HPRA (Health Products Regulatory Authority)

norgine b.v. - ondansetron - orodispersible film - 4 milligram(s) - serotonin (5ht3) antagonists; ondansetron

Ιρλανδία - Αγγλικά - HPRA (Health Products Regulatory Authority)

norgine b.v. - ondansetron - orodispersible film - 8 milligram(s) - serotonin (5ht3) antagonists; ondansetron

Ιρλανδία - Αγγλικά - HPRA (Health Products Regulatory Authority)

norgine b.v. - macrogol 3350; sodium chloride; sodium hydrogen carbonate; potassium chloride - oral solution in sachet - 13.9 g/25 millilitre(s) - osmotically acting laxatives; macrogol, combinations

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

norgine pty ltd - sodium bicarbonate, quantity: 0.0893 g; potassium chloride, quantity: 0.0159 g; macrogol 3350, quantity: 6.563 g; sodium chloride, quantity: 0.1754 g - solution, powder for - excipient ingredients: acesulfame potassium; flavour - for effective relief of constipation in adults. for treatment of chronic constipation in adults and children aged 2 years and older. for resolving faecal impaction, defined as refractory constipation with faecal loading of the rectum, or the rectum and colon, confirmed by physical examination of abdomen and rectum, in adults and children aged 2 years and older. for prevention of recurrence of faecal impaction in children aged 2 years and older. use in children 2 years and older should be limited to 12 weeks except under medical supervision.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

norgine pty ltd - sodium bicarbonate, quantity: 0.0893 g; sodium chloride, quantity: 0.1754 g; macrogol 3350, quantity: 6.563 g; potassium chloride, quantity: 0.0251 g - solution, powder for - excipient ingredients: - for effective relief of constipation in adults. for treatment of chronic constipation in adults and children aged 2 years and older. for resolving faecal impaction, defined as refractory constipation with faecal loading of the rectum, or the rectum and colon, confirmed by physical examination of abdomen and rectum, in adults and children aged 2 years and older. for prevention of recurrence of faecal impaction in children aged 2 years and older. use in children 2 years and older should be limited to 12 weeks except under medical supervision.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

norgine pty ltd - sodium chloride, quantity: 0.1754 g; potassium chloride, quantity: 0.0233 g; macrogol 3350, quantity: 6.563 g; sodium bicarbonate, quantity: 0.0893 g - solution, powder for - excipient ingredients: acesulfame potassium; flavour - for effective relief of constipation in adults. for treatment of chronic constipation in adults and children aged 2 years and older. for resolving faecal impaction, defined as refractory constipation with faecal loading of the rectum, or the rectum and colon, confirmed by physical examination of abdomen and rectum, in adults and children aged 2 years and older. for prevention of recurrence of faecal impaction in children aged 2 years and older. use in children 2 years and older should be limited to 12 weeks except under medical supervision.

Ηνωμένο Βασίλειο - Αγγλικά - MHRA (Medicines & Healthcare Products Regulatory Agency)

norgine pharmaceuticals ltd - estradiol - transdermal patch - 25microgram/24hour

Ηνωμένο Βασίλειο - Αγγλικά - MHRA (Medicines & Healthcare Products Regulatory Agency)

norgine pharmaceuticals ltd - estradiol - transdermal patch - 75microgram/24hour